Bio-Gate has been working with OSSIS for several years, using its HyProtect technology to coat titanium orthopaedic revision implants manufactured by Ossis using 3D printing. Ossis recently accepted an acquisition offer from Zimmer Biomet – a global medical device technology manufacturer. The cooperation with Bio-Gate will continue unchanged and, due to the high quality of the HyProtect coating in the compassionate care sector, the partnership will now even be extended to further regions worldwide via the expanded global network.

Bio-Gate coated titanium implants have already been used in well over a hundred single-patient revision surgeries. Single-patient cases with antimicrobial implants are mainly performed in patients that are at risk of infection due to previous orthopaedic revisions or in cancer patients. This is because in these patient groups, recent infections can lead to amputations or even have life-threatening consequences. Worldwide, patients in the EU, Switzerland, Great Britain, New Zealand, Australia and the USA have been treated with implants coated by Bio-Gate

HyProtect is an ultrathin plasma coating which protects the surfaces of medical implants against bacterial colonisation. It is a combination layer made of pure silver and polysiloxane.

The successful single patient revision cases have led to a strong interest among international clinics and surgeons. Bio-Gate has now accumulated an extensive amount of data from medical devices implanted in humans and can show the high quality of the HyProtect coating in practical-use applications.

Thomas Konradt, Director of Business Development at Bio-Gate, commented: “We are very pleased that our cooperation partner wants to take advantage of the new, worldwide marketing opportunities for our HyProtect coating through the expanded network. The high quality of the HyProtect coating, which greatly reduces the risk of re-infection in patients who are particularly at risk of infection, will thus become even more widely known. In addition, the total number of implants manufactured using the 3D printing process is expected to increase in the future. This will increase the number of single patient compassionate care cases and is extremely helpful in developing our medical technology business into a growth driver.”

For more information, visit: www.bio-gate.de